• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » PRA Fourth Quarter Revenues Jump

PRA Fourth Quarter Revenues Jump

March 6, 2007
CenterWatch Staff

Reston, Va.-based contract research organization (CRO) PRA International reported fourth quarter revenue jumped 18.6% to $82.4 million.Income from operations in the fourth quarter totaled $6.6 million, a 48.4% decrease from $12.8 million in the year-ago quarter.

Net income was $5.7 million, or $0.23 per diluted share, compared with $7.5 million, or $0.31 per diluted share, in the fourth quarter of 2005. On Feb. 28, PRA’s shares fell 13% to $19.93.

PRA reported relatively flat revenue in 2006 and a decrease in operating income compared with last year. PRA reported 2006 service revenue of $303.2 million, compared with $294.7 in 2005.

Operating income in 2006 totaled $33.2 million compared with $51.2 million. The company’s operating margin for 2006 was 10.9%, compared with 17.4% in 2005.

“This is both an exciting and challenging time for PRA, as we are taking immediate actions aimed at getting PRA back on the path to accelerated growth,” said Terry Bieker, chief executive officer of PRA.

The company stated that it will be restructuring into three service areas: early development, product registration, and scientific & medical affairs. PRA also announced it will close its Eaton, N.J., and Ottawa, Canada, facilities. The company stated it does not expect any reduction in staff, and certain project managers and lead CRAs will be able to work remotely.

The cost of the restructuring is expected to be $9 million, with the anticipated annual savings expected to be approximately $4 million.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing